Diego Villa Clé

Diego Villa Clé

Auto-generated profile, based on publicly available information

Diego Villa Clé

Center for Cell-Based Therapy CTC, Regional Blood Center of Ribeirao Preto, University of São Paulo, São Paulo, Brazil; Department of Medical Imaging, Hematology and Oncology, Ribeirao Preto Medical School, University of São Paulo (USP), Ribeirão Preto, Brazil

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2017 in Hematology-American Society Hematology Education Program
Verified
Journal Article
Closed access
RCRodrigo T. Calado
Rodrigo T. Calado
DCDiego V. Clé
Diego V. Clé
Despite significant progress in transplantation by the addition of alternative hematopoietic stem cell sources, many patients with inherited bone marrow failure syndromes are still not eligible for a transplant. In addition, the availability of sequencing panels has significantly improved diagnosis by identifying cryptic inherited cases. Androgens are the main nontransplant therapy for bone marrow failure in dyskeratosis congenita and Fanconi anemia, reaching responses in up to 80% of cases. Danazol and oxymetholone are more commonly used, but virilization and liver toxicity are major adverse events. Diamond-Blackfan anemia is commonly treated with corticosteroids, but most patients eventually become refractory to this treatment and toxicity is limiting. Growth factors still have a role in inherited cases, especially granulocyte colony-stimulating factor in congenital neutropenias. Novel therapies are warranted and thrombopoietin receptor agonists, leucine, quercetin, and novel gene therapy approaches may benefit inherited cases in the future.

7 December 2018 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
FGFernanda Gutierrez-Rodrigues
Fernanda Gutierrez-Rodrigues
FDFlávia S. Donaires
Flávia S. Donaires
APAndré Pinto
André Pinto
AVAlana Vicente
Alana Vicente
LDLaura W. Dillon
Laura W. Dillon
NYNeal S. Young
Neal S. Young
Purpose The acquisition of pathogenic variants in the TERT promoter (TERTp) region is a mechanism of tumorigenesis. In nonmalignant diseases, TERTp variants have been reported only in patients with idiopathic pulmonary fibrosis (IPF) due to germline variants in telomere biology genes. Methods We screened patients with a broad spectrum of telomeropathies (n = 136), their relatives (n = 52), and controls (n = 195) for TERTp variants using a customized massively parallel amplicon-based sequencing assay. Results Pathogenic −124 and −146 TERTp variants were identified in nine (7%) unrelated patients diagnosed with IPF (28%) or moderate aplastic anemia (4.6%); five of them also presented cirrhosis. Five (10%) relatives were also found with these variants, all harboring a pathogenic germline variant in telomere biology genes. TERTp clone selection did not associate with peripheral blood counts, telomere length, and response to danazol treatment. However, it was specific for patients with telomeropathies, more frequently co-occurring with TERT germline variants and associated with aging. Conclusion We extend the spectrum of nonmalignant diseases associated with pathogenic TERTp variants to marrow failure and liver disease due to inherited telomerase deficiency. Specificity of pathogenic TERTp variants for telomerase dysfunction may help to assess the pathogenicity of unclear constitutional variants in the telomere diseases.

5 December 2024 in Blood
Verified
Journal Article
Open access
FGFernanda Gutierrez-Rodrigues
Fernanda Gutierrez-Rodrigues
EGEmma M. Groarke
Emma M. Groarke
NTNatthakan Thongon
Natthakan Thongon
JRJuan Jose Rodriguez-Sevilla
Juan Jose Rodriguez-Sevilla
LCLuiz Fernando B. Catto
Luiz Fernando B. Catto
RCRodrigo T. Calado
Rodrigo T. Calado
Telomere biology disorders (TBDs), caused by pathogenic germ line variants in telomere-related genes, present with multiorgan disease and a predisposition to cancer. Clonal hematopoiesis (CH) as a marker of cancer development and survival in TBDs is poorly understood. Here, we characterized the clonal landscape of a large cohort of 207 patients with TBD with a broad range of age and phenotype. CH occurred predominantly in symptomatic patients and in signature genes typically associated with cancers: PPM1D, POT1, TERT promoter (TERTp), U2AF1S34, and/or TP53. Chromosome 1q gain (Chr1q+) was the commonest karyotypic abnormality. Clinically, multiorgan involvement and CH in TERTp, TP53, and splicing factor genes were associated with poorer overall survival. Chr1q+ and splicing factor or TP53 mutations significantly increased the risk of hematologic malignancies, regardless of clonal burden. Chr1q+ and U2AF1S34 mutated clones were premalignant events associated with the secondary acquisition of mutations in genes related to hematologic malignancies. Similar to the known effects of Chr1q+ and TP53-CH, functional studies demonstrated that U2AF1S34 mutations primarily compensated for aberrant upregulation of TP53 and interferon pathways in telomere-dysfunctional hematopoietic stem cells, highlighting the TP53 pathway as a canonical route of malignancy in TBD. In contrast, somatic POT1/PPM1D/TERTp mutations had distinct trajectories unrelated to cancer development. With implications beyond TBD, our data show that telomere dysfunction is a strong selective pressure for CH. In TBD, CH is a poor prognostic marker associated with worse overall survival. The identification of key regulatory pathways that drive clonal transformation in TBD allows for the identification of patients at a higher risk of cancer development.

20 August 2020 in Blood
Verified
Journal Article
Closed access
PDF file
LCLuiz Fernando B. Catto
Luiz Fernando B. Catto
GBGustavo Borges
Gustavo Borges
APAndre Luiz Pinto
Andre Luiz Pinto
DCDiego V. Clé
Diego V. Clé
FCFernando Chahud
Fernando Chahud
RCRodrigo T. Calado
Rodrigo T. Calado
Haploinsufficiency of GATA2 caused by heterozygous loss-of-function mutations is associated with cytopenias and predisposition to myelodysplasia and AML with other variable extrahematopoietic manifestions, including lymphedema, pulmonary alveolar proteinosis, and hearing loss. The authors report on 2 siblings with the disorder whose father was asymptomatic because of an acquired missense mutation in the affected allele that was restricted to hematopoietic cells; surprisingly, he also had no extrahematopoietic complications.

21 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
FGFernanda Gutierrez-Rodrigues
Fernanda Gutierrez-Rodrigues
EMEric Munger
Eric Munger
XMXiaoyang Ma
Xiaoyang Ma
EGEmma M. Groarke
Emma M. Groarke
YTYoubao Tang
Youbao Tang
NYNeal S. Young
Neal S. Young
The choice to postpone treatment while awaiting genetic testing can result in significant delay in definitive therapies in severely pancytopenic patients. Conversely, inherited bone marrow failure (BMF) misdiagnosis can expose patients to ineffectual and expensive therapies, toxic transplant conditioning regimens, and inappropriate use of an affected family member as a stem cell donor. To predict the likelihood of patients having acquired or inherited BMF, we developed a two-step data-driven machine-learning model using 25 clinical and laboratory variables typically recorded at the initial clinical encounter. For model's development, patients were labeled as having acquired or inherited BMF depending on their genomic data. Datasets were unbiasedly clustered and an ensemble model was trained with cases from the largest cluster of the training cohort (n=359) and validated with an independent cohort (n=127). Cluster A, the largest group, was mostly immune or inherited aplastic anemia, whereas Cluster B was composed of underrepresented BMF phenotypes, and not included in the next step of data modeling due to small sample size. The ensemble model Cluster A-specific was accurate (89%) to predict BMF etiology, correctly predicting inherited and likely immune BMF in 79% and 92% of cases, respectively. Our model represents a practical guide for BMF diagnosis and highlights the importance of clinical and laboratory variables in the initial evaluation, particularly telomere length. Our tool can be potentially used by general hematologists and health care providers not specialized in BMF, and in under-resourced centers, to prioritize patients for genetic testing or for expeditious treatment.

1 December 2015 in Cytotherapy
Verified
Journal Article
Closed access
DCDiego V. Clé
Diego V. Clé
BSBarbara Santana-Lemos
Barbara Santana-Lemos
MTMaria Florencia Tellechea
Maria Florencia Tellechea
KPKaren L. Prata
Karen L. Prata
MOMaristela D. Orellana
Maristela D. Orellana
RCRodrigo T. Calado
Rodrigo T. Calado